GSK's ViiV heads to New York with off-Broadway show about black gay men with HIV

GlaxoSmithKline GSK House in Brentford, UK
GlaxoSmithKline's HIV-focused arm ViiV Healthcare is opening eyes and inspiring action with its immersive theater production bound for New York. (GSK)

ViiV Healthcare’s award-winning theatrical performance about the real-life experiences of black gay men living with HIV debuts in New York this week. “As Much As I Can,” which picked up a Cannes Lions silver award this summer, is about the lives of black gay and bisexual men in Baltimore and Jackson, Mississippi.

ViiV, GlaxoSmithKline’s HIV-focused arm, surfaced the details and scenarios in the show—starting with the fact that Baltimore and Jackson were two of the cities hardest hit by the HIV epidemic—as part of the ethnographic research in its four-year Accelerate! Initiative.

RELATED: HIV drugmakers ViiV, Gilead top 2018 pharma reputation survey

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Set up as a “day in the life” of a group of friends, the immersive theater show probes the difficulties and stigma that black gay and bisexual men with HIV and AIDS face in the South. The New York shows are at Joe’s Pub at the Public Theater, with two performances a night from Sept. 12-16.

“One part moral obligation, one part story within a story, one part extravaganza, 'As Much As I Can' asks all of us what part we are willing to play in ending the AIDS epidemic in the United States," the Public Theater says on its website.

ViiV began the road to the performance with the Accelerate data in hand. Studio Harley & Company encouraged it to go beyond a static white paper or report.

“Culture really allows you to access people at a deeper level on an issue and to drive change. As opposed to seeing a billboard or something, when you’re in this immersive theater experience, you’re there for one and a half hours immersed in a subject and that allows a level of complexity and examination of the issues,” Marc Meachem, head of external affairs in North America for ViiV, said.

RELATED: Merck and ViiV are keeping it real with their TV ads. Which drugmakers will follow?

The show has already run twice in Baltimore, twice in Jackson and one time in Harlem. ViiV is hoping that by taking the show to New York off-Broadway, it will generate more discussion and possible future opportunities to continue.

Earlier shows asked patrons to fill out surveys, Meachem said, and two key ideas rose to the top. “People communicated that this made them look at things differently in terms of HIV, relationships and the number of issues (they face), and also indicated a desire to take action based on what they saw,” he said.

While HIV drugs and messaging have been around for years, still only 51% of people living with HIV in the U.S. are considered virally suppressed. For ViiV, that means the current approach isn’t effective enough.

“We believe ending the epidemic is going to require a different approach than the one we currently use, which is only getting us about one out of every two people virally suppressed. We won’t get there without engaging the communities we’re serving and the communities at risk and involving them in the solution,” Meachem said.

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.